Physician profile
Miracle Wangsuwana
NPI 1750377693
$9,104.41
in general payments reported to CMS, 2019-2025
32 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,643 · 2020: $619 · 2021: $1,391 · 2022: $1,844 · 2023: $1,874 · 2024: $264 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,522 · Education: $86.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,521.95 |
| Education | $86.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,372.73 | 2019-2025 | Tysabri, Vumerity, Spinraza |
| Novartis Pharmaceuticals Corporation | $1,133.45 | 2019-2024 | |
| Emd Serono, INC. | $922.22 | 2019-2025 | Mavenclad, Mavenclad |
| Ucb, INC. | $625.83 | 2019-2023 | Briviact |
| Abbvie INC. | $598.24 | 2021-2023 | Ubrelvy, Qulipta |
| Teva Pharmaceuticals USA, INC. | $594.55 | 2019-2023 | Austedo Xr |
| Genzyme Corporation | $594.16 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $534.95 | 2019-2024 | Nuplazid |
| Lilly USA, LLC | $509.30 | 2019-2023 | Reyvow, Emgality |
| Amgen INC. | $317.06 | 2019-2023 | Aimovig |
| Sk Life Science, INC. | $251.37 | 2022-2023 | Xcopri |
| E.R. Squibb & Sons, L.L.C. | $206.86 | 2021 | |
| Alexion Pharmaceuticals, INC. | $170.95 | 2022-2023 | Ultomiris |
| Celgene Corporation | $144.51 | 2020 | |
| Avanir Pharmaceuticals, INC. | $136.34 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $126.98 | 2022-2025 | Vyvgart |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2020 | |
| Genentech USA, INC. | $120.06 | 2025 | Ocrevus |
| Allergan, INC. | $105.98 | 2020 | |
| Tanabe Pharma America, INC. | $100.00 | 2019 | |
| Janssen Scientific Affairs, LLC | $66.40 | 2022 | |
| Pfizer INC. | $53.17 | 2023-2024 | |
| Livanova USA, INC. | $48.79 | 2022-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Otsuka America Pharmaceutical, INC. | $32.43 | 2023 | Nuedexta |
| Janssen Pharmaceuticals, INC | $32.26 | 2022 | |
| Ptc Therapeutics, INC. | $31.59 | 2024 | Emflaza |
| Sarepta Therapeutics, INC. | $29.00 | 2023 | Exondys 51 |
| Biohaven Pharmaceutical Holding Company LTD. | $28.76 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.47 | 2023 | |
| Sunovion Pharmaceuticals INC. | $22.70 | 2022 | |
| Eisai INC. | $21.94 | 2024 | |
| Banner Life Sciences, LLC | $18.36 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miracle Wangsuwana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.